Novel approaches such as anti-IFN-α antisense oligonucleotides (Viengkhou et al., 2024a), cGAS inhibitors (e.g., antimalarial drugs (mepacrine) (Lama et al., 2019)) and STING inhibitors (Zhang et al., 2023) are currently under investigation but their efficacy still needs to be proven in AGS patients. This evidence concerns the gene STING1 and Aicardi-Goutieres syndrome.